Table 1.
Patient characteristics
| Characteristic | All (n=18) | TILs (n=10) | TIL+DC (n=8) | P value |
| Median age (range), years | 43 (18–64) | 49 (32–63) | 38 (18–64) | 0.2 |
| Sex | ||||
| Female | 9 | 4 | 5 | 0.6 |
| Male | 9 | 6 | 3 | |
| White race | 18 | 10 | 8 | – |
| Melanoma type | ||||
| Cutaneous | 14 | 8 | 6 | 0.8 |
| Acral | 1 | 0 | 1 | |
| Undetermined | 3 | 2 | 1 | |
| Stage | ||||
| 4 M1b | 2 | 0 | 2 | 0.2 |
| 4 M1C | 16 | 10 | 6 | |
| ECOG* | ||||
| 0 | 9 | 2 | 7 | 0.02 |
| 1 | 9 | 8 | 1 | |
| LDH | ||||
| Normal | 15 | 8 | 7 | 1.0 |
| High | 3 | 2 | 1 | |
| BRAF mutation | ||||
| BRAF V600 E | 10 | 7 | 3 | 0.3 |
| BRAF non-V600 E | 2 | 2 | 0 | |
| WT | 4 | 1 | 3 | |
| NRAS mutation | ||||
| Q61K | 3 | 1 | 2 | 0.5 |
| WT | 9 | 6 | 3 | |
| KIT mutation | ||||
| c-KIT | 1 | 1 | 0 | 1.0 |
| WT | 11 | 7 | 4 | |
| Prior systemic therapies | ||||
| None | 2 | 0 | 2 | 0.07 |
| 1 | 7 | 3 | 4 | |
| 2 | 7 | 6 | 1 | |
| 3 | 1 | 1 | 0 | |
| 4 | 1 | 0 | 1 | |
| No of infused TILs (range) | 60.7 (1.7–130) | 38.2 (1.7–99) | 83.2 (16.3–130) | 0.04 |
| No of doses of IL-2 infused | 14 (3–17) | 14 (11–17) | 12.5 (3–17) | 0.3 |
*ECOG status: 0=asymptomatic, 1=symptomatic and ambulatory.
CR, complete response; DC, dendritic cells; ECOG, Eastern Cooperative Oncology Group; IL-2, interleukin-2; irRC, immune-related response criteria; PD, progressive disease; PR, partial response; SD, stable disease; TIL, tumor-infiltrating lympocytes; WT, wild type.